Mechanisms of action of fluvoxamine for COVID-19: a historical review

@article{Hashimoto2022MechanismsOA,
  title={Mechanisms of action of fluvoxamine for COVID-19: a historical review},
  author={Yaeko Hashimoto and Takuji Suzuki and Kenji Hashimoto},
  journal={Molecular Psychiatry},
  year={2022},
  volume={27},
  pages={1898 - 1907}
}
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerates the discovery of prophylactic and therapeutic drugs for persons infected with the virus. Drug repurposing for the COVID-19 pandemic has received particular attention. Increasing clinical data suggest that antidepressant use in early-stage subjects with COVID-19 might be associated with a reduced risk of intubation or death. Among the… 
A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives
TLDR
11 repurposing drugs, their positive and negative health implications, along with traditional herbal alternatives, that harvest strong potential in efficient treatments options against COVID-19, with small or no significant side effects are summarized.
Difficulty in Repurposing Selective Serotonin Reuptake Inhibitors and Other Antidepressants with Functional Inhibition of Acid Sphingomyelinase in COVID-19 Infection
TLDR
Some prematurely optimistic points of view, promoting a large prescription of fluvoxamine in patients with COVID-19, are thought to be reasonably tempered.
Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki
TLDR
There are no therapeutic drugs for long-term symptoms in survivors of COVID-19 and the most common sequelae neurologic headaches, neurological headaches, and functional mobility impairment are found.
Deleterious effects of nervous system in the offspring following maternal SARS-CoV-2 infection during the COVID-19 pandemic
TLDR
This review summarizes the possible mechanisms of the nervous system effects of SARS-CoV-2 infection on their offspring during the pregnancy and analyzes the available prophylactic and treatment strategies to improve the prognosis of fetal-related neuropsychiatric diseases after birth.
Antidepressants for COVID-19: A systematic review
Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment
TLDR
This paper reviews the current literature and synthesizes the available evidence regarding epidemiology, clinical features, neurobiological underpinning, and pharmacological treatment of post-COVID-19 depressive symptoms to counteract the depression disease burden and related years of life lived with disability.
COVID-19 and its clinical severity are associated with alterations of plasma sphingolipids and enzyme activities of sphingomyelinase and ceramidase
TLDR
COVID-19 is associated with a dysregulation of sphingolipid homeostasis in a severity-dependent manner and an accumulation of ceramides by increased enzyme activities leading to ceramide elevation (ASM, NSM) combined with a decreased activity of enzymes (NC) reducing ceramide levels.
The effect of antidepressants on severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis
TLDR
Most of the evidence supports that the use of antidepressant medications, mainly Fluvoxamine may decrease the severity and improve the outcome in hospitalizes patients with sars-cov-2.
Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists
TLDR
It inhibits acid sphingomyelinase activity, the formation of ceramide-enriched membrane domain, and attenuates SARS-CoV-2 cell entry and a potent sigma-1 receptor (S1R) agonist may SARS-CoVs endoplasmic reticulum stress ammation.
Recent Advances in Influenza, HIV and SARS-CoV-2 Infection Prevention and Drug Treatment—The Need for Precision Medicine
TLDR
The views on vaccination and pharmacotherapy, their mutually reinforcing strategic significance in combating pandemics, and the pros and cons of host and virus-targeted drug therapy are shared.
...
...

References

SHOWING 1-10 OF 148 REFERENCES
Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor
  • K. Hashimoto
  • Biology
    European Archives of Psychiatry and Clinical Neuroscience
  • 2021
TLDR
This work proposes repurposing of traditional central nervous system drugs that have a high affinity at the sigma-1 receptor for the treatment of SARS-CoV-2-infected patients and discussed the potential of other CNS candidates such as cutamesine and arketamine.
Old drug fluvoxamine, new hope for COVID-19
TLDR
The emergent use of the old antidepressant fluvoxamine which may block clinical deterioration in mild to moderate patients infected with SARS-CoV-2 is discussed, indicating a key role of the sigma-1 receptor in its action.
Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
TLDR
A body of literature shows important mechanisms of action of fluvoxamine and other SSRIs that could play a role in COVID-19 treatment, which collectively have a direct antiviral effect, regulate coagulopathy or mitigate cytokine storm, which are known hallmarks of severe CO VID-19.
Current status of potential therapeutic candidates for the COVID-19 crisis
COVID-19 and Progesterone: Part 1. SARS-CoV-2, Progesterone and its potential clinical use
  • S. Shah
  • Medicine, Biology
    Endocrine and Metabolic Science
  • 2021
Rapid response to selective serotonin reuptake inhibitors in post-COVID depression
Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine
A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19
TLDR
Postexposure therapy with hydroxychloroquine did not prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons exposed to a PCR-positive case patient.
Drug repurposing in COVID-19: A review with past, present and future
...
...